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Evolving Role of Vorinostat Combined with
Radiation Therapy in the Treatment of Brain
Tumors, from the Lab to the Clinic
Lawrence, Y.R., Wachsberger, P., Liu, Y., Andersen, B., Dicker, A.P.
1

Department of Radiation Oncology, Thomas Jefferson University Hospitals, Philadelphia, PA

Purpose/Objective(s)
Radiation therapy (RT) is a critical element in the treatment of both
brain metastases and glioblastoma (GBM). Temozolomide (TMZ) has
an established role in the upfront treatment of GBM. Down-regulated
mismatch repair (MMR) is a known mechanism of resistance to
TMZ. Vorinostat (SAHA), an HDAC inhibitor, has successfully been
combined with a number of cytotoxic agents, including ionizing
radiation (IR). We performed a series of preclinical and clinical
studies to examine the role of SAHA in the treatment of brain tumors.

Material/Methods, Preclinical
Experiments were performed with 2 GBM cell lines. DNA double
strand breaks were quantified by both neutral-comet assay and
gamma-H2AX immunohistochemistry. For the neutral comet assay
the ‘olive moment’ represents DNA damage. For gamma-H2AX
assay, the percentage of cells with more than 3 foci was scored.

MMR. Despite this, clonogenic radiation survival assays demonstrated
TMZ + SAHA to be more effective than TMZ alone in potentiating
the cytotoxic effect of IR.

Results, Clinical
Initial results indicate that low dose Vorinostat combined with RT is
well tolerated, dose escalation is continuing.

Conclusion
SAHA shows promise as a radiosensitzer for brain tumors. The
discrepancy between DNA-damage and clonogenic-cell-survival
assays suggests that SAHA’s mechanism of radiosensitization may
involve more than potentiation of DNA-damage. The efficacy
of Vorinostat combined with temozolomide requires further
investigation. Future clinical trials will investigate short-course doseescalated drug schedules.

Methods, Clinical
A multicenter dose-escalation phase I trial, based on Fibonacci 3+3
design is being conducted. Whole-brain radiation is delivered in
daily fractions of 2.5 Gy over 3 weeks (total dose 37.5 Gy). Vorinostat
is delivered once daily on days of radiation therapy. Dose levels:
increase from 200 mg PO qd to 400 mg PO qd in subsequent cohorts.
Expected total accrual: 9-18 patients. Primary endpoint: tolerability.

Results, Preclinical
In the absence of drug, radiation-induced DNA-double strand breaks
were almost completely repaired within 24-hours. Both TMZ + IR,
and SAHA + IR increased the olive moment compared to IR alone (24
hour post IR time-point). Surprisingly, when TMZ and SAHA were
combined together with IR, the olive moment decreased to 6.5 as
compared to TMZ + IR alone 8.7 (p<0.05). Similarly, in the absence of IR,
SAHA was found to decrease TMZ-induced DNA damage. Comparable
results were obtained with gamma-H2AX assay and with the 2nd cell
line. On qPCR, SAHA decreased expression of key genes involved in
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